KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Change in Account Payables: 2009-2018

Historic Change in Account Payables for Alnylam Pharmaceuticals (ALNY) over the last 10 years, with Dec 2018 value amounting to $15.5 million.

  • Alnylam Pharmaceuticals' Change in Account Payables fell 431.18% to -$30.1 million in Q3 2019 from the same period last year, while for Sep 2019 it was $12.4 million, marking a year-over-year increase of 6.22%. This contributed to the annual value of $15.5 million for FY2018, which is 413.38% up from last year.
  • Per Alnylam Pharmaceuticals' latest filing, its Change in Account Payables stood at $15.5 million for FY2018, which was up 413.38% from -$4.9 million recorded in FY2017.
  • Alnylam Pharmaceuticals' 5-year Change in Account Payables high stood at $15.5 million for FY2018, and its period low was -$4.9 million during FY2017.
  • Over the past 3 years, Alnylam Pharmaceuticals' median Change in Account Payables value was $10.1 million (recorded in 2016), while the average stood at $6.9 million.
  • As far as peak fluctuations go, Alnylam Pharmaceuticals' Change in Account Payables soared by 502.51% in 2016, and later slumped by 148.91% in 2017.
  • Yearly analysis of 5 years shows Alnylam Pharmaceuticals' Change in Account Payables stood at $8.8 million in 2014, then tumbled by 81.04% to $1.7 million in 2015, then surged by 502.51% to $10.1 million in 2016, then plummeted by 148.91% to -$4.9 million in 2017, then skyrocketed by 413.38% to $15.5 million in 2018.